CN120571006A - 用于治疗乙型肝炎感染的方法和组合物 - Google Patents

用于治疗乙型肝炎感染的方法和组合物

Info

Publication number
CN120571006A
CN120571006A CN202510720759.5A CN202510720759A CN120571006A CN 120571006 A CN120571006 A CN 120571006A CN 202510720759 A CN202510720759 A CN 202510720759A CN 120571006 A CN120571006 A CN 120571006A
Authority
CN
China
Prior art keywords
epitope
seq
amino acid
acid sequence
hbsag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510720759.5A
Other languages
English (en)
Chinese (zh)
Inventor
雷纳·沃尔什
S·卢卡尼尼
汉斯·内特尔
罗纳德·法科尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melbourne Health
Original Assignee
Melbourne Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melbourne Health filed Critical Melbourne Health
Publication of CN120571006A publication Critical patent/CN120571006A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202510720759.5A 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物 Pending CN120571006A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862669663P 2018-05-10 2018-05-10
US62/669,663 2018-05-10
PCT/US2019/031483 WO2019217654A1 (en) 2018-05-10 2019-05-09 Methods and compositions for the treatment of hepatitis b infection
CN201980046550.8A CN112513063A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980046550.8A Division CN112513063A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物

Publications (1)

Publication Number Publication Date
CN120571006A true CN120571006A (zh) 2025-09-02

Family

ID=68466904

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202510720759.5A Pending CN120571006A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物
CN201980046550.8A Pending CN112513063A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物
CN202410997275.0A Pending CN119113097A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980046550.8A Pending CN112513063A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物
CN202410997275.0A Pending CN119113097A (zh) 2018-05-10 2019-05-09 用于治疗乙型肝炎感染的方法和组合物

Country Status (10)

Country Link
US (4) US11773141B2 (https=)
EP (2) EP3810625B1 (https=)
JP (2) JP2021522864A (https=)
KR (2) KR20250027279A (https=)
CN (3) CN120571006A (https=)
AU (2) AU2019267680C1 (https=)
CA (1) CA3099726A1 (https=)
ES (1) ES2985391T3 (https=)
PL (1) PL3810625T3 (https=)
WO (1) WO2019217654A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244940A1 (en) * 2024-05-21 2025-11-27 Clearb Therapeutics Ltd. Methods and compositions for mrna- and dna-based treatment of hepatitis b infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CN100381463C (zh) * 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
EP2292642A1 (en) 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
AU2015259470A1 (en) * 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
AU2019267680C1 (en) 2025-02-27
EP3810625A1 (en) 2021-04-28
JP2024105291A (ja) 2024-08-06
CN119113097A (zh) 2024-12-13
ES2985391T3 (es) 2024-11-05
AU2019267680B2 (en) 2024-07-25
KR20250027279A (ko) 2025-02-25
AU2019267680A1 (en) 2020-11-26
EP3810625B1 (en) 2024-05-22
EP3810625A4 (en) 2022-05-11
WO2019217654A1 (en) 2019-11-14
US12202862B2 (en) 2025-01-21
US11773141B2 (en) 2023-10-03
US20250333450A1 (en) 2025-10-30
KR20210010872A (ko) 2021-01-28
JP2021522864A (ja) 2021-09-02
EP4389222A2 (en) 2024-06-26
CN112513063A (zh) 2021-03-16
EP4389222A3 (en) 2024-08-28
CA3099726A1 (en) 2019-11-14
US20220002349A1 (en) 2022-01-06
US20250145669A1 (en) 2025-05-08
AU2024227453A1 (en) 2024-11-21
US20240150412A1 (en) 2024-05-09
PL3810625T3 (pl) 2025-03-03

Similar Documents

Publication Publication Date Title
Pondé Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
Zhang et al. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
EP2858674B1 (en) An antibody composition for prevention or treatment of mutant hepatitis b virus infection
Tang et al. A novel linear neutralizing epitope of hepatitis E virus
US20250333450A1 (en) Methods and compositions for the treatment of hepatitis b infection
Menne et al. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection
HK40106023A (en) Methods and compositions for the treatment of hepatitis b infection
Wang et al. HBcAg18–27 epitope fused to HIV-Tat49–57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice
HK40040491B (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491A (en) Methods and compositions for the treatment of hepatitis b infection
TW202547530A (zh) 用於基於ｍＲＮＡ及ＤＮＡ之Ｂ型肝炎感染治療的方法及組合物
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
CN104474548B (zh) 预防和/或治疗慢性病毒感染的产品及方法
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
Cardell Studies on hepatitis B vaccination and factors associated with the vaccine response
Thompson et al. Hepatitis B virus
Shamseldin Development of Research Tools for Studying Hepatitis B Virus
KR20060117920A (ko) 치료용 약학적 조성물
Onu Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen
GB2440528A (en) Antigen-antibody complexes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination